Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Has results × Tolvaptan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Saline Solution 9 enzalutamide 8 Fentanyl 8 Docetaxel 8 Bevacizumab 8 nilotinib 7 Everolimus 7 Cyclophosphamide 7 Bupivacaine 7 Sodium Chloride 6 Paclitaxel 6 Lidocaine 6 Letrozole 6 Erlotinib Hydrochloride 6 Dexamethasone 6 Carboplatin 6 Oxycodone 5 Nivolumab 5 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5 Capecitabine 5 fludarabine 4 Trastuzumab 4 Tranexamic Acid 4 Tobacco Use Cessation Devices 4 Tacrolimus 4 Surveys and Questionnaires 4 Rituximab 4 Morphine 4 Leuprolide 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01199198 2020-09-23

Tolvaptan in Hyponatremic Cancer Patients

M.D. Anderson Cancer Center

Phase 4 Completed

52 enrolled 7 charts

Hyponatremia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡